Industry Research Reports

Home > Reports > Pharma & Healthcare > Metabolic Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Metabolic Disease Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published Date: 2024-01-08

Pages: 109 Pages

Report ld: 3009596

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Metabolic Disease Drugs Market Size(US$)

CAGR 2024-2030

10.1%

Market Size,2030

USD 160,970

Million

Market Snapshot

Market Size in 2024 (Value)

US$ 90,370 million

Market Forecast in 2030(Value)

US$ 160,970 million

CAGR

10.1%

Years Considered

2019-2030

Base Year

2024

Forecast Period

2024-2030

Source: Secondary research, interviews with experts, and QYResearch analysis

Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.

The global market for Metabolic Disease Drugs was estimated to be worth US$ 82150 million in 2023 and is forecast to a readjusted size of US$ 160970 million by 2030 with a CAGR of 10.1% during the forecast period 2024-2030

The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.

MARKET SEGMENTATION

By Company

Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Beohrigher Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other

Segment by Application

Hospital Pharmacy
Retail Pharmacy

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Metabolic Disease Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Metabolic Disease Drugs by region & country, by Type, and by Application.

The Metabolic Disease Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disease Drugs.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Metabolic Disease Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Metabolic Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Metabolic Disease Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Metabolic Disease Drugs Product Introduction

1.2 Global Metabolic Disease Drugs Market Size Forecast

1.3 Metabolic Disease Drugs Market Trends & Drivers

1.3.1 Metabolic Disease Drugs Industry Trends

1.3.2 Metabolic Disease Drugs Market Drivers & Opportunity

1.3.3 Metabolic Disease Drugs Market Challenges

1.3.4 Metabolic Disease Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Metabolic Disease Drugs Players Revenue Ranking (2023)

2.2 Global Metabolic Disease Drugs Revenue by Company (2019-2024)

2.3 Key Companies Metabolic Disease Drugs Manufacturing Base Distribution and Headquarters

2.4 Key Companies Metabolic Disease Drugs Product Offered

2.5 Key Companies Time to Begin Mass Production of Metabolic Disease Drugs

2.6 Metabolic Disease Drugs Market Competitive Analysis

2.6.1 Metabolic Disease Drugs Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Metabolic Disease Drugs Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Glycogen Metabolism Disease Drug

3.1.2 Lipid Metabolism Disease Drug

3.1.3 Amino Acid Metabolism Drug

3.1.4 Other

3.2 Global Metabolic Disease Drugs Sales Value by Type

3.2.1 Global Metabolic Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Metabolic Disease Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Metabolic Disease Drugs Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacy

4.1.2 Retail Pharmacy

4.2 Global Metabolic Disease Drugs Sales Value by Application

4.2.1 Global Metabolic Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Metabolic Disease Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Metabolic Disease Drugs Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Metabolic Disease Drugs Sales Value by Region

5.1.1 Global Metabolic Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Metabolic Disease Drugs Sales Value by Region (2019-2024)

5.1.3 Global Metabolic Disease Drugs Sales Value by Region (2025-2030)

5.1.4 Global Metabolic Disease Drugs Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Metabolic Disease Drugs Sales Value, 2019-2030

5.2.2 North America Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Metabolic Disease Drugs Sales Value, 2019-2030

5.3.2 Europe Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Metabolic Disease Drugs Sales Value, 2019-2030

5.4.2 Asia Pacific Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Metabolic Disease Drugs Sales Value, 2019-2030

5.5.2 South America Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Metabolic Disease Drugs Sales Value, 2019-2030

5.6.2 Middle East & Africa Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Metabolic Disease Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Metabolic Disease Drugs Sales Value

6.3 United States

6.3.1 United States Metabolic Disease Drugs Sales Value, 2019-2030

6.3.2 United States Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Metabolic Disease Drugs Sales Value, 2019-2030

6.4.2 Europe Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Metabolic Disease Drugs Sales Value, 2019-2030

6.5.2 China Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Metabolic Disease Drugs Sales Value, 2019-2030

6.6.2 Japan Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Metabolic Disease Drugs Sales Value, 2019-2030

6.7.2 South Korea Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Metabolic Disease Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Metabolic Disease Drugs Sales Value, 2019-2030

6.9.2 India Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Metabolic Disease Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck

7.1.1 Merck Profile

7.1.2 Merck Main Business

7.1.3 Merck Metabolic Disease Drugs Products, Services and Solutions

7.1.4 Merck Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.1.5 Merck Recent Developments

7.2 Novartis

7.2.1 Novartis Profile

7.2.2 Novartis Main Business

7.2.3 Novartis Metabolic Disease Drugs Products, Services and Solutions

7.2.4 Novartis Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.2.5 Novartis Recent Developments

7.3 Takeda Pharmaceutical

7.3.1 Takeda Pharmaceutical Profile

7.3.2 Takeda Pharmaceutical Main Business

7.3.3 Takeda Pharmaceutical Metabolic Disease Drugs Products, Services and Solutions

7.3.4 Takeda Pharmaceutical Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.3.5 Astra Zeneca Recent Developments

7.4 Astra Zeneca

7.4.1 Astra Zeneca Profile

7.4.2 Astra Zeneca Main Business

7.4.3 Astra Zeneca Metabolic Disease Drugs Products, Services and Solutions

7.4.4 Astra Zeneca Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.4.5 Astra Zeneca Recent Developments

7.5 Beohrigher Ingelheim

7.5.1 Beohrigher Ingelheim Profile

7.5.2 Beohrigher Ingelheim Main Business

7.5.3 Beohrigher Ingelheim Metabolic Disease Drugs Products, Services and Solutions

7.5.4 Beohrigher Ingelheim Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.5.5 Beohrigher Ingelheim Recent Developments

7.6 KOWA

7.6.1 KOWA Profile

7.6.2 KOWA Main Business

7.6.3 KOWA Metabolic Disease Drugs Products, Services and Solutions

7.6.4 KOWA Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.6.5 KOWA Recent Developments

7.7 Kythera

7.7.1 Kythera Profile

7.7.2 Kythera Main Business

7.7.3 Kythera Metabolic Disease Drugs Products, Services and Solutions

7.7.4 Kythera Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.7.5 Kythera Recent Developments

7.8 Fuji yakuhin

7.8.1 Fuji yakuhin Profile

7.8.2 Fuji yakuhin Main Business

7.8.3 Fuji yakuhin Metabolic Disease Drugs Products, Services and Solutions

7.8.4 Fuji yakuhin Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.8.5 Fuji yakuhin Recent Developments

7.9 LG Life Science

7.9.1 LG Life Science Profile

7.9.2 LG Life Science Main Business

7.9.3 LG Life Science Metabolic Disease Drugs Products, Services and Solutions

7.9.4 LG Life Science Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.9.5 LG Life Science Recent Developments

7.10 Metsubishi Tanabe Pharma

7.10.1 Metsubishi Tanabe Pharma Profile

7.10.2 Metsubishi Tanabe Pharma Main Business

7.10.3 Metsubishi Tanabe Pharma Metabolic Disease Drugs Products, Services and Solutions

7.10.4 Metsubishi Tanabe Pharma Metabolic Disease Drugs Revenue (US$ Million) & (2019-2024)

7.10.5 Metsubishi Tanabe Pharma Recent Developments

8 Industry Chain Analysis

8.1 Metabolic Disease Drugs Industrial Chain

8.2 Metabolic Disease Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Metabolic Disease Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Metabolic Disease Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Metabolic Disease Drugs Market Trends

Table 2. Metabolic Disease Drugs Market Drivers & Opportunity

Table 3. Metabolic Disease Drugs Market Challenges

Table 4. Metabolic Disease Drugs Market Restraints

Table 5. Global Metabolic Disease Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Metabolic Disease Drugs Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Metabolic Disease Drugs Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Metabolic Disease Drugs Product Type

Table 9. Key Companies Time to Begin Mass Production of Metabolic Disease Drugs

Table 10. Global Metabolic Disease Drugs Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disease Drugs as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Metabolic Disease Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Metabolic Disease Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Metabolic Disease Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Metabolic Disease Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Metabolic Disease Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Metabolic Disease Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Metabolic Disease Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Metabolic Disease Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Metabolic Disease Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Metabolic Disease Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Metabolic Disease Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Metabolic Disease Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Metabolic Disease Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Metabolic Disease Drugs Sales Value by Region (2019-2024) & (%)

Table 27. Global Metabolic Disease Drugs Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Metabolic Disease Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Metabolic Disease Drugs Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Metabolic Disease Drugs Sales Value, (2025-2030) & (US$ Million)

Table 31. Merck Basic Information List

Table 32. Merck Description and Business Overview

Table 33. Merck Metabolic Disease Drugs Products, Services and Solutions

Table 34. Revenue (US$ Million) in Metabolic Disease Drugs Business of Merck (2019-2024)

Table 35. Merck Recent Developments

Table 36. Novartis Basic Information List

Table 37. Novartis Description and Business Overview

Table 38. Novartis Metabolic Disease Drugs Products, Services and Solutions

Table 39. Revenue (US$ Million) in Metabolic Disease Drugs Business of Novartis (2019-2024)

Table 40. Novartis Recent Developments

Table 41. Takeda Pharmaceutical Basic Information List

Table 42. Takeda Pharmaceutical Description and Business Overview

Table 43. Takeda Pharmaceutical Metabolic Disease Drugs Products, Services and Solutions

Table 44. Revenue (US$ Million) in Metabolic Disease Drugs Business of Takeda Pharmaceutical (2019-2024)

Table 45. Takeda Pharmaceutical Recent Developments

Table 46. Astra Zeneca Basic Information List

Table 47. Astra Zeneca Description and Business Overview

Table 48. Astra Zeneca Metabolic Disease Drugs Products, Services and Solutions

Table 49. Revenue (US$ Million) in Metabolic Disease Drugs Business of Astra Zeneca (2019-2024)

Table 50. Astra Zeneca Recent Developments

Table 51. Beohrigher Ingelheim Basic Information List

Table 52. Beohrigher Ingelheim Description and Business Overview

Table 53. Beohrigher Ingelheim Metabolic Disease Drugs Products, Services and Solutions

Table 54. Revenue (US$ Million) in Metabolic Disease Drugs Business of Beohrigher Ingelheim (2019-2024)

Table 55. Beohrigher Ingelheim Recent Developments

Table 56. KOWA Basic Information List

Table 57. KOWA Description and Business Overview

Table 58. KOWA Metabolic Disease Drugs Products, Services and Solutions

Table 59. Revenue (US$ Million) in Metabolic Disease Drugs Business of KOWA (2019-2024)

Table 60. KOWA Recent Developments

Table 61. Kythera Basic Information List

Table 62. Kythera Description and Business Overview

Table 63. Kythera Metabolic Disease Drugs Products, Services and Solutions

Table 64. Revenue (US$ Million) in Metabolic Disease Drugs Business of Kythera (2019-2024)

Table 65. Kythera Recent Developments

Table 66. Fuji yakuhin Basic Information List

Table 67. Fuji yakuhin Description and Business Overview

Table 68. Fuji yakuhin Metabolic Disease Drugs Products, Services and Solutions

Table 69. Revenue (US$ Million) in Metabolic Disease Drugs Business of Fuji yakuhin (2019-2024)

Table 70. Fuji yakuhin Recent Developments

Table 71. LG Life Science Basic Information List

Table 72. LG Life Science Description and Business Overview

Table 73. LG Life Science Metabolic Disease Drugs Products, Services and Solutions

Table 74. Revenue (US$ Million) in Metabolic Disease Drugs Business of LG Life Science (2019-2024)

Table 75. LG Life Science Recent Developments

Table 76. Metsubishi Tanabe Pharma Basic Information List

Table 77. Metsubishi Tanabe Pharma Description and Business Overview

Table 78. Metsubishi Tanabe Pharma Metabolic Disease Drugs Products, Services and Solutions

Table 79. Revenue (US$ Million) in Metabolic Disease Drugs Business of Metsubishi Tanabe Pharma (2019-2024)

Table 80. Metsubishi Tanabe Pharma Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Metabolic Disease Drugs Downstream Customers

Table 84. Metabolic Disease Drugs Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Metabolic Disease Drugs Product Picture

Figure 2. Global Metabolic Disease Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Metabolic Disease Drugs Report Years Considered

Figure 5. Global Metabolic Disease Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Metabolic Disease Drugs Revenue in 2023

Figure 7. Metabolic Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Glycogen Metabolism Disease Drug Picture

Figure 9. Lipid Metabolism Disease Drug Picture

Figure 10. Amino Acid Metabolism Drug Picture

Figure 11. Other Picture

Figure 12. Global Metabolic Disease Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Metabolic Disease Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Hospital Pharmacy

Figure 15. Product Picture of Retail Pharmacy

Figure 16. Global Metabolic Disease Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Metabolic Disease Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 19. North America Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

Figure 24. South America Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 25. South America Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa Metabolic Disease Drugs Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa Metabolic Disease Drugs Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions Metabolic Disease Drugs Sales Value (%), (2019-2030)

Figure 29. United States Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 31. United States Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 35. China Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 36. China Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 37. China Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 47. India Metabolic Disease Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 48. India Metabolic Disease Drugs Sales Value by Type (%), 2023 VS 2030

Figure 49. India Metabolic Disease Drugs Sales Value by Application (%), 2023 VS 2030

Figure 50. Metabolic Disease Drugs Industrial Chain

Figure 51. Metabolic Disease Drugs Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

KEY QUESTIONS ADDRESSED BY THE REPORT

What was the global market size of Metabolic Disease Drugs in 2024? zhanKai

The global market size of Metabolic Disease Drugs in 2024 was 90370 Million USD.

What was the global market size of Metabolic Disease Drugs in 2030? shouQi

Which companies rank high in the global Metabolic Disease Drugs market? shouQi

What is the annual compound growth rate of the global Metabolic Disease Drugs market size from 2024 to 2030? shouQi

Which region is expected to have the highest market share? shouQi

Related Reports

Global Metabolic Disease Drugs Market Research Report 2025
The global market for Metabolic Disease Drugs was valued at US$ 90370 million in the year 2024 and is projected to reach a revised size of US$ 175600 million by 2031, growing at a CAGR of 10.1% during the forecast period.
Published Date: 2025-01-01
Pages: 75
USD 2900.00
(Single User License)
Global Metabolic Disease Drugs Market Insights, Forecast to 2030
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published Date: 2024-04-12
Pages: 108
USD 4900.00
(Single User License)
Global Metabolic Disease Drugs Market Research Report 2024
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published Date: 2024-01-12
Pages: 89
USD 2900.00
(Single User License)

Global Metabolic Disease Drugs Market Research Report 2025
The global market for Metabolic Disease Drugs was valued at US$ 90370 million in the year 2024 and is projected to reach a revised size of US$ 175600 million by 2031, growing at a CAGR of 10.1% during the forecast period.
Published: 2025-01-01
Pages: 75
USD 2900.00 (Single User License)
Global Metabolic Disease Drugs Market Insights, Forecast to 2030
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published: 2024-04-12
Pages: 108
USD 4900.00 (Single User License)
Global Metabolic Disease Drugs Market Research Report 2024
Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
Published: 2024-01-12
Pages: 89
USD 2900.00 (Single User License)